Explains the hot, red, prickling upper-body flush that lands ~15-30 min after immediate-release nicotinic acid — the most user-noticed effect of niacin and the reason most users abandon the lipid-lowering dose. Niacin binds GPR109A (HCA2 / HM74A / PUMA-G), a Gi/o-coupled GPCR identified as the niacin receptor by Tunaru 2003. In adipocytes GPR109A drives the anti-lipolytic effect (the lipid-lowering mechanism); but in skin it sits on epidermal Langerhans cells and keratinocytes, where activation triggers a phospholipase A2 → arachidonic acid → cyclooxygenase (COX-1 in Langerhans, COX-2 in keratinocytes) → prostaglandin D2 cascade (Benyo 2005, Benyo 2006, Hanson 2010). PGD2 released into the dermis activates DP1 receptors on cutaneous vascular smooth muscle → vasodilation, warmth, redness, and the characteristic tingle-itch. The flush is dose-dependent, saturable, and tachyphylactic (most users desensitize within 2-4 weeks). Aspirin 325 mg pre-dose blunts it by inhibiting COX, and laropiprant (a DP1 antagonist) was developed specifically to suppress it (Cheng 2006) — though laropiprant-niacin (Tredaptive / Cordaptive) was withdrawn after the HPS2-THRIVE outcome trial. Acipimox produces less flush than niacin per equivalent receptor occupancy; extended-release formulations (Niaspan) blunt peak plasma to stay below the flush threshold. Mechanism is distinct from histamine flush (antihistamines don't blunt it) and from carcinoid flush (no serotonin involvement).
Organ Systems
integumentary
immune-hematologic
Pathway Steps
niacin → GPR109A activation — via niacin binds Gi-coupled HCA2 / GPR109A / HM74A on Langerhans cells + keratinocytes (Tunaru 2003). The niacin flush is a receptor-mediated, prostaglandin-driven reflex, not a direct vascular effect. Niacin (nicotinic acid) activates GPR109A (HCA2/PUMA-G), the Gi-coupled receptor that also mediates its lipid effects and that butyrate activates. Identifying this receptor explained why flushing and lipid-lowering trace to one target.
GPR109A activation → cytosolic Ca²⁺ rise + PLA2 activation — via Gi/o βγ → PLA2 activation → arachidonic acid mobilization from membrane phospholipids. On skin immune cells (Langerhans cells, keratinocytes), GPR109A activation raises cytosolic Ca²⁺ and activates phospholipase A2, liberating arachidonic acid. This is the first committed step toward the prostaglandin burst that causes the flush — where the signal leaves the niacin receptor for the eicosanoid pathway.
PLA2 activation → PGD2 synthesis (COX-1 Langerhans, COX-2 keratinocytes) — via arachidonic acid → COX-1 (Langerhans) / COX-2 (keratinocytes) → PGH2 → PGD2 synthase; aspirin blunts this step. Arachidonic acid is converted to prostaglandin D2 (and E2) by cyclooxygenases — COX-1 in Langerhans cells (the early flush) and COX-2 in keratinocytes (the later, sustained phase). This is why aspirin (a COX inhibitor) taken beforehand blunts the niacin flush, a common clinical workaround.
PGD2 synthesis (COX-1 Langerhans, COX-2 keratinocytes) → DP1 receptor activation on dermal vascular smooth muscle — via paracrine PGD2 → Gs-coupled DP1 on cutaneous arterioles → ↑cAMP → vasodilation. The PGD2 released acts on the DP1 receptor of dermal vascular smooth muscle. The finding that DP1 antagonism suppresses flushing led to laropiprant, a DP1 blocker co-formulated with niacin to prevent the flush (though the combination was later withdrawn for lack of outcome benefit).
DP1 receptor activation on dermal vascular smooth muscle → cutaneous vasodilation (flush: warmth, redness, tingle, itch) — via DP1-mediated arteriolar dilation of face/neck/upper trunk; laropiprant (DP1 antagonist) specifically blocks flush. DP1 activation relaxes dermal vascular smooth muscle, producing cutaneous vasodilation — the warmth, redness, tingling, and itch of the flush, typically over the face and upper body. Though harmless, this flush is the main reason patients quit niacin, hence extended-release forms and aspirin pretreatment.
Known Modulators
niacin (activator) — GPR109A (HCA2 / HM74A). the perpetrator — immediate-release doses ≥100 mg saturate skin GPR109A; extended-release (Niaspan) and slow titration build tachyphylaxis within 2-4 weeks; tachyphylaxis is the reason chronic users stop flushing
aspirin (inhibitor) — COX-1 → blocks PGD2 synthesis upstream of DP1. 325 mg aspirin 30-60 min before niacin blunts the flush by ~half by inhibiting COX-1 in Langerhans cells; does not blunt the lipid-lowering effect (different mechanism in adipocytes)